Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium

Rhea-AI Summary

Entasis Therapeutics Holdings (NASDAQ: ETTX) announced participation in A.G.P.'s Virtual Healthcare Symposium on November 19, 2020. The event will feature 1-on-1 virtual investor meetings. Interested investors should contact their A.G.P. representative. Entasis is focused on developing novel antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria. Their pipeline includes candidates addressing Acinetobacter baumannii, Neisseria gonorrhoeae, Enterobacteriaceae, and Pseudomonas infections.

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19^th, 2020.

The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with Company management should contact their A.G.P. representative.

About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.

Entasis Company Contact         
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Investor Relations Contact
James Salierno
The Ruth Group
(646) 536-7028
jsalierno@theruthgroup.com

Media Contact
Annika Parrish
The Ruth Group
(720) 412-9042
aparrish@theruthgroup.com

FAQ

What is the date of Entasis Therapeutics' participation in the A.G.P. Virtual Healthcare Symposium?

Entasis Therapeutics will participate in the A.G.P. Virtual Healthcare Symposium on November 19, 2020.

How can investors meet with Entasis Therapeutics' management during the symposium?

Investors interested in meeting with Entasis Therapeutics' management should contact their A.G.P. representative.

What types of infections do Entasis Therapeutics' products target?

Entasis Therapeutics focuses on serious infections caused by multidrug-resistant Gram-negative bacteria, including Acinetobacter baumannii and Neisseria gonorrhoeae.

What is the stock symbol for Entasis Therapeutics?

The stock symbol for Entasis Therapeutics is ETTX.

What are some products in Entasis Therapeutics' pipeline?

Entasis Therapeutics' pipeline includes sulbactam-durlobactam for Acinetobacter, zoliflodacin for gonorrhea, ETX0282CPDP for Enterobacteriaceae, and ETX0462 for Pseudomonas.